Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06TME
|
|||
| Former ID |
DNCL001684
|
|||
| Drug Name |
MEDI-546
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interferon alpha/beta receptor 1 (IFNAR1) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Natural killer cell mediated cytotoxicity | ||||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | Interferon alpha/beta signaling | |||
| Regulation of IFNA signaling | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Interferon type I signaling pathways | ||||
| Interferon alpha/beta signaling | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8258). | |||
| REF 2 | Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.